Clinical Trials in Denver

Showing 2241-2260 of 15,604 trials

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

NCT06856499

The purpose of this study is to learn about the safety and tolerability of Cirtuvivint in combination with Olaparib in platinum resistant ovarian cancer. The study also aims to determine the recommended dose of the combination therapy. If a participant is a good fit for the study, and they enroll in the study, they will: * Visit the clinic often at the beginning of the study for physical exams, blood draws, vital signs, and other study and routine care procedures. After the first two months participants will visit the clinic every 28 days. * Take the study medications, Cirtuvivint and Olaparib. Participants will take Olaparib every day. Participants will either take Cirtuvivint 5 days per week or 2 days per week.

Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer

University of Colorado, Denver50 participantsStarted Dec 2025

Aurora, Colorado, United States • Aurora, Colorado, United States

TERMINATEDPhase 28.4 miles

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

NCT01995058

This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).

Prostate CancerCastration Resistant Prostate CancerProstatic Neoplasms

Exelixis54 participantsStarted Feb 2014

Scottsdale, Arizona, United States • Sedona, Arizona, United States • Tucson, Arizona, United States +17 more locations

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Find Trials by Condition in Denver

Human Laboratory Study of Apremilast for Alcohol Use Disorder

Investigation of the Two Level Simplify® Cervical Artificial Disc

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study

Neuronavigated aiTBS for TRD

Evaluating Therapeutic Electrical Stimulation to Improve Nerve Healing After Surgical Repair of Digital Nerve Injuries

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP